Zhejiang Ausun Pharmaceutical Co., Ltd. Class A

Zhejiang Ausun Pharmaceutical Co., Ltd. Class A

SSSE:603229
6.71
CNY
-0.02
(-0.30%)
-0.01EPS
6.86BMarket Cap
Apr 23Next Earn

Total Valuation

CNY

As of September 30, 2026, Zhejiang Ausun Pharmaceutical Co., Ltd. Class A carries a market capitalization of 6.86B, placing it among publicly traded companies globally. Its enterprise value stands at 6.22B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

Market Cap6.86B
Enterprise Value6.22B

Important Dates

Zhejiang Ausun Pharmaceutical Co., Ltd. Class A's next confirmed earnings release is scheduled for April 23, 2027.

Earnings Date4/23/2027

Share Statistics

As of September 30, 2026, Zhejiang Ausun Pharmaceutical Co., Ltd. Class A has 830.30M shares outstanding.

Shares Outstanding830.30M

Valuation Ratios

These figures are as of September 30, 2026. The price-to-sales ratio is 8.95, and the price-to-book ratio stands at 3.00.

PS Ratio8.95
PB Ratio3.00
P/TBV Ratio3.21

Enterprise Valuation

These figures are as of September 30, 2026. The EV/Sales ratio of 8.21 reflects the premium investors pay for the company's revenue stream, a useful check when earnings are depressed or negative. These enterprise value multiples are built on an enterprise value of 6.22B versus a market cap of 6.86B, with the gap driven by net debt and cash on the balance sheet.

EV / Sales8.21

Financial Position

As of September 30, 2026, Zhejiang Ausun Pharmaceutical Co., Ltd. Class A maintains a current ratio of 3.06, meaning it holds 3.1x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 13.77, indicating elevated leverage, while an interest coverage ratio of -2.33 demonstrates limited ability to service its debt obligations.

Current Ratio3.06
Quick Ratio1.79
Debt / Equity13.77
Debt / EBITDA-13.94
Interest Coverage-2.33

Financial Efficiency

CNY

Over the twelve months ended September 30, 2026, Zhejiang Ausun Pharmaceutical Co., Ltd. Class A posted a negative return on equity (ROE) of -0.19, meaning shareholder capital produced losses rather than profits. Return on assets (ROA) is negative at -0.15, reflecting losses generated across the asset base. The company generates approximately 570,069.66 in revenue per employee across its workforce of 1,328.00, a quick read on workforce productivity versus industry peers. Inventory turnover of 1.01 indicates how many times Zhejiang Ausun Pharmaceutical Co., Ltd. Class A sells and replaces its inventory over a year, a key working capital efficiency ratio.

Return on Equity (ROE)-0.19
Return on Assets (ROA)-0.15
Revenue Per Employee570,069.66
Employee Count1,328.00
Inventory Turnover1.01

Taxes

CNY

Over the twelve months ended September 30, 2026, Zhejiang Ausun Pharmaceutical Co., Ltd. Class A recorded an income tax benefit of -18.98M rather than an expense, typically from losses, carryforwards, or the release of a tax provision. The company reported a pretax loss of -23.51M and -4.53M in bottom-line net income, so the effective tax rate carries little signal until profitability returns.

Income Tax-18.98M

Stock Price Statistics

CNY

As of the close on November 17, 2026, Zhejiang Ausun Pharmaceutical Co., Ltd. Class A's stock has declined approximately 35.29% over the past 52 weeks. The 50-day moving average sits at 7.58, while the 200-day moving average is 8.74.

52-Week Price Change-35.29%
50-Day Moving Average7.58
200-Day Moving Average8.74

Income Statement

CNY

Over the twelve months ended September 30, 2026, Zhejiang Ausun Pharmaceutical Co., Ltd. Class A generated 757.05M in revenue and converted that into -4.53M in net income, yielding earnings per share of -0.01. EBITDA reached -22.61M, while operating income came in at 31.00M.

Revenue757.05M
Gross Profit363.44M
Operating Income31.00M
Pretax Income-23.51M
Net Income-4.53M
EBITDA-22.61M
EBIT-22.61M
Earnings Per Share (EPS)-0.01

Balance Sheet

CNY

As of September 30, 2026, Zhejiang Ausun Pharmaceutical Co., Ltd. Class A holds 954.86M in cash and equivalents against 315.14M in total debt, resulting in a net debt position of -659.01M. Total book value stands at 2.29B, with working capital of 1.10B providing operational flexibility.

Cash & Cash Equivalents954.86M
Total Debt315.14M
Net Debt-659.01M
Equity (Book Value)2.29B
Book Value Per Share2.76
Working Capital1.10B

Cash Flow

CNY

These figures cover the twelve months ended September 30, 2026.

Capital Expenditures-96.44M

Margins

Over the twelve months ended September 30, 2026, Zhejiang Ausun Pharmaceutical Co., Ltd. Class A posted a gross margin of 48.01, reflecting its pricing power and cost economics. The operating margin of 4.09 and net profit margin of -0.60 provide insight into operational efficiency.

Gross Margin48.01
Operating Margin4.09
Pretax Margin-3.11
Profit Margin-0.60
EBITDA Margin-2.99

Dividends & Yields

CNY

Over the twelve months ended September 30, 2026, Zhejiang Ausun Pharmaceutical Co., Ltd. Class A paid dividends of 0.08 per share. The dividend payout ratio of -1,382.34 is negative because earnings are negative, so the dividend is being paid out of something other than profits, a key gauge of how sustainable the dividend is and how much room remains for future dividend growth. Total shareholder yield reaches 1.25, combining dividends paid with share buybacks and debt reduction for a fuller picture of capital returned to Zhejiang Ausun Pharmaceutical Co., Ltd. Class A shareholders.

Dividend Per Share0.08
Payout Ratio-1,382.34
Shareholder Yield1.25

Stock Splits

Zhejiang Ausun Pharmaceutical Co., Ltd. Class A's most recent stock split took place on July 12, 2024 with a 5:7 split ratio.

Last Split Date7/12/2024
Split Ratio5:7

Scores

As of September 30, 2026, Zhejiang Ausun Pharmaceutical Co., Ltd. Class A has an Altman Z-Score of 8.17, well above the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.

Altman Z-Score8.17